Viatris faces legal setback to market generics for Merck’s diabetic drugs

Sep. 22, 2022 7:45 AM ETMerck & Co., Inc. (MRK)VTRSBy: Dulan Lokuwithana, SA News Editor6 Comments


Marilyn Nieves

  • Merck (NYSE:MRK) has dealt a blow to Viatris' (VTRS) efforts to bring generic versions of its blockbuster drugs Januvia and Janumet after a favorable court ruling in a patent lawsuit regarding sitagliptin, the active ingredient

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.